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AML PATIENTS LACKING KIR LIGAND FOR DONOR KIR EXHIBIT IN-
CREASED OVERALL SURVIVAL IN HLA-IDENTICAL SIBLING TRANSPLANTS
Hsu K.C.1, Taylor C.A.2, O’Reilly R.J.1, Horowitz M.M.2, Arkun K.1,
Pinto C.1, DuPont, B.1 1. Memorial Sloan-Kettering Cancer Center,
New York, NY; 2. Medical College of Wisconsin, Milwaukee, WI.
Killer Ig-like receptors (KIRs) comprise a group of inhibitory
and activating receptors that interact with speciﬁc HLA class I
ligands and are found on the surface of NK cells. Previous studies
have analyzed the HLA genotypes of donor-recipient pairs and
have drawn conclusions about the effect of donor KIR on trans-
plant outcome based on ligand presence alone. It is known, how-
ever, that the KIR and HLA chromosomal regions segregate in-
dependently from each other, thereby laying challenge to studies
that have predicted the effect of KIR genotype based solely on
HLA genotype. Our studies analyze KIR effects on transplant
outcome by examining donor KIR genotypes together with their
class I ligands from donors and patients with myeloid and lym-
phoid leukemias undergoing allogeneic hematopoietic stem cell
transplantation at two transplant centers. In AML patients receiv-
ing T-cell depleted (TCD) transplants from HLA-identical sib-
lings (MCW n  76), we found that the absence of patient HLA
ligand for donor inhibitory KIR is associated with higher overall
survival (OS) (p  0.027). This beneﬁt was also noted in AML
patients receiving unmodiﬁed allografts from HLA-identical sib-
lings (MSKCC n  27), where the beneﬁt on OS may be specif-
ically related to the lack of HLA-Bw4 epitope for donor KIR3DL1
(p  0.0001), resulting in a decrease in disease relapse (p  0.02).
Furthermore, there may be some additive effect of donor
KIR2DS3 in the setting of inhibitory KIR ligand absence in AML
patients receiving TCD transplants from HLA-identical siblings
(MSKCC n  59, p  0.053; MCW n  76, p  0.029). These
results could be extended to AML patients receiving TCD allo-
grafts from unrelated donors, where again lack of Bw4 epitope
leads to higher OS (p  0.073) and lower risk for relapse (p 
0.03). Interestingly, there was no KIR-driven beneﬁt seen on OS
or relapse in CML or ALL patients receiving either TCD, unmod-
iﬁed, HLA-identical related or unrelated allografts.
These data demonstrate an apparent alloreactive effect in AML
patients when an HLA ligand for donor inhibitory KIR is absent.
This effect is seen even in HLA-identical sibling transplants, im-
plying that auto-reactive NK clones exist in a suppressed or “an-
ergic” state within individuals who may themselves lack the appro-
priate HLA-ligands for their KIR. However, these NK clones (or
their progenitors) are not deleted, as evidenced by their alloreac-
tivity upon regeneration in the HLA-identical sibling recipient.
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DENILEUKIN DIFTITOX (ONTAK) AS TARGETED THERAPY AGAINST
STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Ho V.T.1,2,4, Hochberg E.1,2,4, Zahrieh D.1, Cutler C.1,2,4, Steckel S.3,
Lee S.J.1,2,4, Alyea E.P.1,2,4, Ritz J.1,2,4, Soiffer R.J.1,2,4,3,
Antin, J.H.1,2,4 1. Dana-Farber Cancer Institute, Boston, MA; 2.
Brigham and Women’s Hospital, Boston, MA; 3. Ligand Pharmaceuti-
cals, San Diego, CA; 4. Harvard Medical School, Boston, MA.
Denileukin diftitox (ONTAK®) is a recombinant fusion protein
composed of human interleukin-2 linked to the membrane trans-
location and catalytic domains of diphtheria toxin. ONTAK has
potent selective killing activity against activated lymphocytes that
express the high or intermediate afﬁnity interleukin-2 receptor
(IL-2R). Monoclonal antibodies that target the IL-2R have dem-
onstrated clinical activity against acute GVHD. ONTAK may be
superior to these agents because it does not rely on secondary
effector mechanisms for cell kill, and entry of a few molecules into
the cytoplasm may be sufﬁcient to induce apoptosis. Furthermore,
because ONTAK selectively destroys activated T-cells and spares
resting lymphoid populations, valuable immune function and re-
constitution potential may be preserved. We have completed a
phase I study to assess the dosing of ONTAK in patients with
steroid-refractory GVHD after allogeneic HSCT. Thirty patients
(3 related donor, 27 unrelated donor) were treated for grade II (n
10), grade III (n 15), or grade IV (n 5) steroid-refractory acute
GVHD. Seven received ONTAK at dose level I (9 g/kg IV on
day 1 and 15), eighteen were treated on dose level II (9 g/kg IV
days 1,3,5,15,17,19), ﬁve were treated on dose level III (9 g/kg IV
days 1-5, 15-19). At dose level III, 4 of 5 subjects developed
dose-limiting toxicity (1 acute renal failure, 3 hepatic transaminase
elevation). Therefore, dose level II was deemed the maximum
tolerated dose (MTD). In all patients, elevated transaminases re-
solved promptly upon withdrawal of ONTAK. Only 2 (7%) de-
veloped infusional reactions with transient hypotension. Twenty-
four patients were evaluable for GVHD response. After 4 weeks, 8
(33%) had complete GVHD resolution (CR) of, 9(38%) had par-
tial response (PR), for an overall response rate of 71%. Among the
9 PRs, 4 subsequently entered CR without additional GVHD
therapy, resulting in an overall CR of 50%. Response was highest
at the MTD, where 6 (46%) achieved CR, and 3 (23%) had PR, all
of whom eventually converted to CR (overall CR  69%). Of the
24 patients evaluable for GVHD response, 9(38%) are alive, with
the longest survivor being GVHD free at 20 months. Our results
show that ONTAK at a dose schedule of 9 g/kg IV on days
1,3,5,15,17,19 is tolerable and has promising activity for steroid-
refractory GVHD. Future studies using the MTD are warranted to
investigate the potential role of ONTAK as primary treatment of
acute GVHD.
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THE GIFT OF LIFE COMES WITH A PRICE: THE IMPACT OF HEMATO-
POIETIC CELL TRANSPLANT ON THE LONG-TERM QUALITY OF LIFE OF
SURVIVORS AND THEIR SPOUSES
Bishop M.M.1, Hahn E.A.2, Cella D.2, Brady M.J.3, Andrykowski M.A.4,
Beaumont J.2, Rizzo J.D.5, Wingard, J.R.1 1. University of Florida,
Gainesville, FL; 2. Evanston Northwestern Healthcare/Northwestern
University, Evanston, IL; 3. Independent Consultant, Iron Mountain,
MI; 4. University of Kentucky College of Medicine, Lexington, KY; 5.
Medical College of Wisconsin, Milwaukee, WI.
The impact of hematopoietic cell transplant (HCT) on the qual-
ity of life (QOL) of spouse/partners of survivors is understudied.
We collected extensive quality of life data from 662 HCT survivors
from 40 North American transplant centers registered with the
IBMTR/ABMTR. Survivors were randomly selected from four
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